Important Interactions of Immunosuppressants With Experimental Therapies for Novel Coronavirus Disease (COVID-19): How to Act
- PMID: 32433189
- DOI: 10.1097/FTD.0000000000000766
Important Interactions of Immunosuppressants With Experimental Therapies for Novel Coronavirus Disease (COVID-19): How to Act
Comment on
-
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187464 Free PMC article. Clinical Trial.
References
-
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020.
-
- Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transpl. 2015;15:1313–1322.
-
- Yilmaz M, Gökengin D, Bozbiyik O, et al. Kidney transplant in a human immunodeficiency virus-positive patient: case report of drug interactions. Exp Clin Transpl. 2017. doi: 10.6002/ect.2017.0013. - DOI
-
- Badri PS, Parikh A, Coakley EP, et al. Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection. Ther Drug Monit. 2016;38:640–645.
-
- Floren LC, Christians U, Zimmerman JJ, et al. Sirolimus oral bioavailability increases ten-fold with concomitant ketoconazole. Clin Pharmacol Ther. 1999;65:159.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources